证券日报网讯8月4日晚间，正海生物（300653）发布公告称，公司将于2025年8月27日召开2025年第一 次临时股东会。本次股东会将审议《关于补选非独立董事的议案》等多项议案。 ...

正海生物2025半年报 ...

Core Insights - The company, Zhenghai Biological, reported a revenue of 188 million yuan for the first half of 2025, representing a year-on-year decline of 5.14% [1] - The net profit attributable to shareholders was 46.49 million yuan, down 45.97% compared to the previous year [1] Business Overview - The main business of the company focuses on the research, production, and sales of biological regenerative materials [1] - The company has established a comprehensive business platform that includes research and development, clinical trials, registration, production, quality assurance, and sales [1] - As of now, the company has received approval for 13 medical device products, of which 9 are classified as Class III medical devices [1] - The products are widely used in various medical fields, including oral and maxillofacial surgery, neurosurgery, orthopedics, and dermatology [1]

Core Viewpoint - Zhenghai Biological's stock closed at 23.13 yuan, with a PE ratio of 34.44, marking a new low in 84 days, and a total market capitalization of 4.163 billion yuan [1] Company Summary - Zhenghai Biological specializes in the research, production, and sales of bio-regenerative materials, with key products including oral repair membranes, absorbable dura mater patches, bone repair materials, skin repair membranes, surgical packing sponges, self-etching adhesives, active biological bone, dura mater patches, phosphoric acid etchants, and dental pit and fissure sealants [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023 [1] Financial Performance - For the first half of 2025, the company reported revenue of 188 million yuan, a year-on-year decrease of 5.14%, and a net profit of 46.4857 million yuan, down 45.97%, with a gross profit margin of 83.92% [1] Industry Summary - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, placing Zhenghai Biological at 69th in the industry ranking [1] - The company's PE ratio is significantly lower than the industry average, indicating potential undervaluation [2]

Group 1 - The core viewpoint of the article is that Zhenghai Bio reported a decline in both revenue and net profit for the first half of 2025 compared to the same period in the previous year [2] - The company's operating revenue for the first half of 2025 was 188 million yuan, representing a year-on-year decrease of 5.14% [2] - The net profit attributable to the parent company was 46.49 million yuan, showing a significant year-on-year decline of 45.97% [2]

Group 1 - The company, Zhenghai Biological, announced a revenue of 188 million yuan for the first half of 2025, representing a year-on-year decrease of 5.14% [1] - The net profit attributable to shareholders of the listed company was 46 million yuan, showing a significant year-on-year decline of 45.97% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 40 million yuan, which is a year-on-year decrease of 46.77% [1]

Core Viewpoint - Zhenghai Biological reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 188 million yuan, a year-on-year decrease of 5.14% [2] - The net profit attributable to shareholders was around 46.49 million yuan, reflecting a significant year-on-year decline of 45.97% [2] - Basic earnings per share were reported at 0.26 yuan, down 45.83% compared to the previous year [2]

每经AI快讯，正海生物（SZ 300653，收盘价：23.13元）8月4日晚间发布公告称，公司第四届第八次董 事会会议于2025年8月4日以通讯方式召开。会议审议了《关于2025年半年度报告全文及其摘要的议案》 等文件。 每经头条（nbdtoutiao）——"我们也深陷残酷价格战"！德资巨头中国区高管警告：智驾绝不能免费， 否则会给全行业带来灾难 （记者 胡玲） 2024年1至12月份，正海生物的营业收入构成为：医疗器械占比100.0%。 截至发稿，正海生物市值为42亿元。 ...

烟台正海生物科技股份有限公司董事会 审计委员会工作细则 第一章 总 则 第一条 为强化烟台正海生物科技股份有限公司（以下简称"公司"）的董事会决策能力， 做到事前审计、专业审计，确保董事会对经理层的有效监督，完善公司治理结构，根据《中 华人民共和国公司法》等法律、法规、规范性文件以及《烟台正海生物科技股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，并结合公司实际情况，制定本工作细则。 第二条 董事会审计委员会是董事会下设的专门委员会，主要负责审核公司财务信息及 其披露、监督及评估内外部审计工作和内部控制工作，并按照《公司法》及《公司章程》的 规定，行使《公司法》规定的监事会的职权。 第二章 人员组成 第三条 审计委员会成员由 3 名董事组成，审计委员会成员应当为不在公司担任高级 管理人员的董事，其中独立董事应当过半数，并由独立董事中会计专业人士担任召集人。 第四条 审计委员会委员（以下简称"委员"）由董事长、1/2 以上独立董事或者全体董 事的 1/3 以上提名，并由董事会选举产生。 第五条 审计委员会设主任委员（召集人）一名，由独立董事中会计专业人士担任，负 责主持委员会工作。委员会主任委员由董 ...

烟台正海生物科技股份有限公司 董事会议事规则 烟台正海生物科技股份有限公司 董事会议事规则 第一章 总 则 第一条 为了进一步规范本公司董事会的议事方式和决策程序，促使董事和 董事会有效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人 民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》、《上市公司 治理准则》、《深圳证券交易所创业板股票上市规则》（以下简称《上市规则》）等 法律、法规、规范性文件和《烟台正海生物科技股份有限公司章程》（以下称《公 司章程》）的规定，制订本规则。 （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或者减少注册资本、发行债券或其他证券及上市方案； （六）拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更公 司形式的方案； （七）审议本规则第四条至第六条规定的交易事项； （八）决定内部管理机构的设置； （九）聘任或者解聘公司总经理、董事会秘书，并决定其报酬事项和奖惩事 项；根据总经理的提名，聘任或者解聘公司副总经理、财务负责人等高级管理人 员，并决定其报酬事项和奖惩事项； ...